What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
about
Vitamin A and Alzheimer's diseaseAlzheimer mechanisms and therapeutic strategiesγ-Secretase inhibitors and modulators.New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsAmyloid-β and APP deficiencies cause severe cerebrovascular defects: important work for an old villainDBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease.Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes.Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model.The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment.Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.The γ-secretase complex: from structure to function.Cognitive health begins at conception: addressing dementia as a lifelong and preventable conditionClustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.Alzheimer's disease: a clinical practice-oriented review.Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice.The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.Neurotoxicity of biologically targeted agents in pediatric cancer trialsCellular and animal models for high-throughput screening of therapeutic agents for the treatment of the diseases of the elderly in general and Alzheimer's disease in particular(†).Purinergic receptors as potential therapeutic targets in Alzheimer's disease.Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation.Why our patients (and we) need basic science researchInvolvement of presenilin holoprotein upregulation in calcium dyshomeostasis of Alzheimer's disease.γ-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells.Disease-modifying drugs in Alzheimer's disease.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Alzheimer's disease: the challenge of the second century.Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.Biomarkers for Alzheimer's disease: showing the way or leading us astray?Animal models of Alzheimer disease.Aiming at neuroblastoma and hitting other worthy targets.Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Gamma secretase inhibitors: a patent review (2013 - 2015).γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.Production of active glycosylation-deficient γ-secretase complex for crystallization studies.Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators.Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.
P2860
Q22242414-1F77932E-E847-4087-97C6-5D420ACF1984Q22252311-D8279130-CEF1-4009-A0F5-B62C810B9D5CQ26830462-AB0272D9-C86A-4439-92F8-F83471ED6593Q26866006-29C3CC86-D4AE-4938-9E0C-C74957F9D06EQ27305806-10285BF5-7A00-4377-BF2D-32AC6D1E9833Q30412535-9BB33D7A-0C59-409B-BCB2-DDC8DA3BDAD0Q31057900-16747EAC-2A0F-483D-9437-5D5F10043050Q34073334-66DB6B9A-C69D-493C-836A-CD2D23495FBDQ34157421-F832A999-4A7A-48C6-98FB-00DEA9F938D5Q34584761-40518AF4-BBFE-4B5F-B9CB-591FE74E2650Q34656871-6BDD7B40-3159-4E94-BD14-E002EEB39B6DQ34677532-FE25DD33-91B0-4D64-9A8C-A17734E21883Q35046906-05C28689-342B-4033-A83F-2E943159A4A4Q35052443-D2313232-9CDD-48F1-9371-125BC3A95E81Q35758963-FB5D7316-424F-4ACB-B312-6E3B94CDF333Q35899503-6A1EEA9E-8EED-46C8-B851-C1EE1C7A13F9Q36378706-72B57074-54AC-4175-8BF1-05B2AA37A740Q36562023-DD05A772-980D-40A0-93A0-9B0915979C17Q36766221-4C2FAF40-3193-49C2-8385-2AB49823FAD9Q36837509-5AA56AE5-19AC-44A9-8402-F50B043F0881Q36844881-480BEBA8-02AB-47CB-A53B-C73EEB37165DQ36928744-84E105C5-AF92-4598-9837-0D54AD57B042Q37027326-54F85C90-C640-439F-B8E5-2729EAC78E95Q37293997-17EAF363-F939-4115-AEEA-AF71779CE787Q37318868-048A0AEF-8033-4430-8DFB-70F3590E10C2Q37390739-EB409C2D-277A-4147-9048-7C3FB1FE4F6FQ37559812-B589A074-4D77-48DF-BAA5-073CC67CE796Q37862502-2DA06C41-597E-444A-B59D-E1A837A4F8F6Q37987587-6CB28C9D-63BE-4B4B-ACAF-3C8021DE88AAQ38024256-50704D24-4242-483A-BC3A-8601ECE76EADQ38045853-92507D45-077D-4212-B81A-E6D7BFE4D499Q38098145-F22004AC-AD95-4657-8AFC-5F34B3A1D8FDQ38123209-EBD7A357-6F05-4E9C-A6EC-C22713E29355Q38127470-07758F32-4575-4C1C-ABB3-27EFEE5631CFQ38738605-0E52DD7B-1BF0-4C6B-9819-805083DBDD22Q38766437-A2E5ECEE-3CBD-46EE-9B9D-D4F938498366Q38865583-66D249D8-C89D-4565-A1C6-65A282F66DBDQ39514771-AD1B2945-D0B9-4E1B-A54E-26418FE824EBQ39629610-5EF2817C-12F8-4705-86E7-EA5146B809EBQ39728463-67FB26B0-B8C8-4BDF-B12E-91B61361B88D
P2860
What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
@en
What the halted phase III γ-secretase inhibitor trial may
@nl
type
label
What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
@en
What the halted phase III γ-secretase inhibitor trial may
@nl
prefLabel
What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
@en
What the halted phase III γ-secretase inhibitor trial may
@nl
P2860
P356
P1433
P1476
What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us
@en
P2093
Nina F Schor
P2860
P304
P356
10.1002/ANA.22365
P50
P577
2011-02-01T00:00:00Z